

Certificate of Analysis

Cell Count	1.8 Million per vial
Viability	93%
CD8+	98.07%
CD8+ Neg Tetramer+	0.05%
CD8+ MART-1 Tetramer+	95.26%
Sterility Testing	Negative for bacteria and fungi

Donor Information



Donor ID	358
Gender	Female
Age	54
Race	Caucasian
Height	66 in
Weight	230 lbs
ABO Type	O negative

HLA Typing

	Allele 1	Allele 2
HLA-A	02:01	02:01
HLA-B	44:02	15:01
HLA-C	03:03	05:01
HLA-DRB1	01:03	04:04


Donors are tested for the blood borne pathogens (HIV-1 and 2, Hepatitis B, Hepatitis C and HTLV-1) and are negative. Cells should still be handled as if potentially infectious following biosafety level 2 procedures.

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.



Negative tetramer: HLA-A*02:01 - PE iTag MHC Tetramer (MBL International, Woburn, MA).
 MART-1 tetramer: MART-126-35 A27L peptide (ELAGIGILTV)/HLA-A*02:01 - PE iTag MHC Tetramer (MBL International, Woburn, MA)

IFN-gamma Secretion



20,000 anti-MART-1 T cells were plated in a 96-well round-bottom plate with 20,000 T2 cells (a B-LCL expressing HLA-A*02:01) alone or in the presence of increasing concentrations of HLA-A*02:01 restricted native MART-127-35 nonamer peptide (AAGIGILTV), or HLA-A*02:01 restricted analog (A27L) MART-126-35 decamer peptide (ELAGIGILTV) or HLA-A*02:01 restricted CMVpp65 peptide (NLVPMVATV). Culture supernatants were collected after 18-24 hours of incubation. IFN- γ concentration was analyzed using the Meso Scale Discovery and presented as pg/mL

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.